Research Article

The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Da-Hai Hu,1,2 Wan-Ching Wong,1 Jia-Xin Zhou,1,2 Ji Luo,2 Song-Wang Cai,3 Hong Zhou,4 and Hui Tang5,6

1Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China
2International School, Jinan University, Guangzhou, Guangdong 510632, China
3Department of Thoracic Surgery, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China
4Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China
5Clinical Medicine Research Institute, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China
6Jiangmen Maternity and Child Health Care Hospital, Huizhou 52900, China

Correspondence should be addressed to Song-Wang Cai; caisongwang@jnu.edu.cn, Hong Zhou; zhouhongjnu@foxmail.com, and Hui Tang; feifei_085@126.com

Received 23 May 2022; Revised 8 June 2022; Accepted 23 June 2022; Published 9 July 2022

Academic Editor: Jiang Pi

Copyright © 2022 Da-Hai Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. To determine if the use of the Proton Pump Inhibitors (PPI) impacts the clinical efficacy of Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC), a meta-analysis was conducted. Method. Eleven studies from PubMed, EMBASE, Cochrane Library, Web of Science, and other databases up to May 2022, were selected. The pertinent clinical outcomes were assessed by applying the Progression-free survival (PFS), Overall Survival (OS), Hazard Ratio (HR), and 95% Confidence Interval (CI). Result. This study included eleven articles containing 7,893 NSCLC patients. The result indicated that PPI use was dramatically related to poor OS (HR: 1.30 [1.10–1.54]), and poor PFS (HR: 1.25 [1.09–1.42]) in cases of patients treated with ICIs. With regard to the subgroup analysis, PPI use was dramatically associated with poor OS (Europe: HR = 1.48 [1.26, 1.74], Worldwide: HR = 1.54 [1.24, 1.91]), and poor PFS (Europe: HR = 1.36 [1.18, 1.57], Worldwide: HR = 1.34 [1.16, 1.55]) in patients from Europe and multi-center studies across the world, poor OS in patients with age less than or equal to 65 (HR = 1.56 [1.14, 2.15]), poor PFS in patients aged more than 65 (HR = 1.36 [1.18, 1.57]), poor OS for patients receiving with PD-1 (HR = 1.37 [1.04, 1.79]), poor PFS for patients receiving with PD-L1 (HR = 1.33 [1.19, 1.49]), and poor OS (−30: HR = 1.89 [1.29, 2.78], ±30: HR = 1.44 [1.27, 1.64]) and poor PFS (−30: HR = 1.51 [1.11, 2.05], ±30: HR = 1.32 [1.20, 1.45]) for patients who received PPI at 30 days before and/or after starting the ICIs treatment. Conclusion. Our meta-analysis indicated that PPI combined with ICIs in the treatment of NSCLC patients could result in poor OS and PFS. PPI use should be extremely cautious in clinical practices to avoid the impact on the efficacy of the ICIs.

1. Introduction

Non-small cell lung cancer (NSCLC) is one of the most common cancers, accounting for about 80% of all lung cancers. According to incomplete statistics, NSCLC kills 1.6 million people worldwide each year [1]. The main pathologic types of NSCLC include squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [2]. Compared with small cell carcinoma, the growth and division rate of cancer cells in NSCLC is slow, and the diffusion and metastasis occur relatively late. However, after systematic treatment, the 5-year survival rate of some NSCLC patients is still not ideal [3]. Nowadays, for NSCLC, a single treatment plan, such as surgery, radiotherapy, or immunotherapy, may be difficult to achieve ideal results. Therefore, combination therapy has gradually come into people’s vision, such as
chemotherapy or radiotherapy after surgery, and Proton Pump Inhibitor (PPI) combined with Immune Checkpoint Inhibitors (ICIs). However, the clinical efficacy of these combined therapies for patients is still unclear, and more relevant studies are needed to explore.

As an effective inhibitor of gastric acid secretion, the PPI has been used widely to treat the hypersecretion of gastric acid and other related diseases around the world, for instance, Gastroesophageal Reflux Disease (GERD) and gastric ulcers [4]. Studies have indicated that use of PPI for a long time could increase the risk of related tissue histopathological changes, and could lead to the disorder of normal colonies in the gastrointestinal tract, greatly increasing the risk of gastrointestinal infection [5–7]. In recent years, since PPI could enhance the sensitivity of cancer patients towards chemotherapy, hence, it has gained prominence in the field of tumor treatment [8, 9]. Nevertheless, the efficacy and risk of the use of PPI are different for various cancer types [10]. However, the efficacy of the use of PPI in the treatment of cancer is not very clear, and needs further research.

Presently, the cancer immunotherapy mainly includes the following three kinds, ICIs and adoptive cell therapy, operating the immunologic defense to differentiate, and attack tumor cells [11]. Among them, the ICIs have been used in a widespread manner in the neighborhood of tumor treatment, greatly improving the strategy of treating related cancer. Cytotoxic drug T lymphocyte associated antigen 4 (CTLA-4) inhibitor, programmed cell death ligand 1 (PD-L1), as well as programmed cell death 1 (PD-1) are the three kinds of ICIs widely used clinically [12, 13]. However, certain controversial aspects of cancer immunotherapy still remain. As the immune system could be over activated during immunotherapy, bring with it, it could bring serious side effects to the patients, and the adverse reactions in individual cases were serious and even life-threatening at times [14]. These illustrated that the clinical efficacy of ICIs was not very clear. Today, with the popularity of the combination therapy, the ICIs are often combined with the PPI. In one study, for NSCLC patients, the PPI combined with ICIs led to a negative result, nevertheless, in case of the melanoma patients, it produced a positive result [15]. Hence, it is controversial whether the clinical efficacy of ICIs in NSCLC is related to the use of the PPI.

This study was intended to determine if there was any correlation between the clinical efficacy of the ICIs in NSCLC and the use of PPI.

2. Materials and Method

2.1. Search Strategy. The literatures involved in this study were independently screened by two researchers (D. H. and W. W.) to determine whether they met the inclusion or exclusion criteria, and any differences would be resolved by consensus with third party researcher (J. Z.). Our search strategy is as illustrated in Figure 1, searching the studies from PubMed, EMBASE, Cochrane Library, and Web of Science databases up to May 2022. The keywords searched were, “Non-small Cell Lung Cancer,” “Non-Small Cell Lung Carcinoma,” “Lung Carcinoma, Non-Small-Cell,” “programmed death-ligand 1 inhibitor,” “PD-L1 inhibitor,” “Immunotherapy,” “programmed death receptor 1 inhibitor,” “PD-1 inhibitor,” “cytotoxic T lymphocyte antigen-4 inhibitor,” “CTLA-4 inhibitor,” and “proton pump inhibitor.”

2.2. The Criteria for Inclusion and Exclusion. The criteria for inclusion were: (1) The collected literature involving the usage of PPI and the clinical efficacy in NSCLC of the ICIs; (2) Use of PPI done before and/or after starting the ICIs treatment; (3) Patients received just the ICIs treatments or combined with PPI; (4) The inclusion of the non-using PPI and using PPI groups; and (5) The outcome of study should contain the Overall Survival (OS) and/or Progression-Free Survival (PFS), Hazard Ratio (HR), and 95% Confidence Intervals (CIs). The exclusion criteria were as under: (1) Repetitive studies; (2) Non-human studies; (3) The study report was not in English; and (4) The reviews and meta-analyses, or the case report.

2.3. Data Extracting/. The result information like 95% CI of OS and/or PFS, HR, duration of exposure to PPI, cancer type, PPI treatment, type of ICIs treatment, sample size, age, region, first author, and year of publication were extracted from the studies that were included. To reduce the influence of the confounding factors, the multivariate analysis was selected to calculate the HRs value to the extent possible.

2.4. Quality Assessment. The literature included in the study were retrospective studies and the quality evaluation of research referred to the Newcastle—Ottawa Quality Assessment Scale (NOS) [16]. The evaluation was scored with respect to three aspects, selection of topic, comparability, and evaluation of results. For the NOS system, a score of 6 or more of studies was defined as high quality [17].

2.5. Statistical Analysis. The HR and 95% CI of OS and/or PFS were meta-analyzed by applying the Review Manager 5.4 software for Win, while HR >1.0 was considered as poor OS or poor PFS in the outcomes. The funnel plot assessed the publication bias. The heterogeneity of the studies included was assessed by $I^2$ statistics, and the sensitivity analysis, Begg’s tests, and Egger’s tests of studies were evaluated by Stata 15 software for Win. When $I^2$ was greater than 50%, it was regarded that the research had great heterogeneity, and the random effect model was adopted. The extracted data were analyzed by the dichotomous, Mantel–Haenszel method model. In this study, $P$ values <0.05 were considered as statistically significant.

3. Result

3.1. Selection of Study. Figure 1 illustrates the flow chart of the selection of studies. 52 studies that were searched from the database were included in this study, with 9 supplemental studies from other databases. After repetitive studies
(n = 19) and studies of unrelated topics (n = 14) were deleted, with 42 articles being selected. Subsequently, according to the above including and excluding criteria, 17 articles were excluded, including reviews, and meta-analysis, case report (n = 8), no result posted (n = 4), and no NSCLC (n = 5). Finally, 11 published articles in total were selected in our study up to May 2022.

3.2. Characteristics of the Studies Included. As shown in Table 1, eleven published articles containing 7,893 patients were included in the study. Between the 11 studies, 3, 2, 2, 2, 2 studies were performed in Asia, Worldwide, Europe, America, and Oceania, respectively. Most patients were treated with PPI before and/or shortly after the beginning of ICIs, and the type of ICI treatment was dominated by PD-(L)1. In the Table 2, the 11 studies included were retrospective studies with result information of OS and/or PFS. The HR values were extracted from the univariate analysis of 5 studies and multivariate analysis of another 5 studies. The NOS score of all the included studies was greater than or equal to 6, which could be considered as high-quality articles.

3.3. The Association between PPI Use and OS. As indicated in Figure 2(a), 11 studies with 7,893 NSCLC patients were selected to perform meta-analysis for OS. The result revealed that in patients who had received ICIs treatment, the use of PPI was found to be significantly associated with poor OS (HR: 1.30, 95% CI: 1.10–1.54, P = 0.003). Nevertheless, significant heterogeneity existed in this analysis (I² = 82%, P < 0.001).

3.4. The Association between PPI Use and PFS. As shown in Figure 2(b), 7 studies with 3,454 NSCLC patients were selected to perform meta-analysis for PFS. The results revealed that PPI use was significantly associated with poor PFS in the patients who had received ICIs treatment (HR: 1.25, 95% CI: 1.09–1.42, P = 0.001), with significant heterogeneity (I² = 56%, P = 0.04).

3.5. Subgroup Analysis of OS. To further assess the influence of PPI use in OS, the subgroup analyses were performed with regard to region, age, sample size, immunotherapy drugs, and duration of PPI exposure. As illustrated in Table 3, in terms of the region subgroup, PPI use was significantly related to poor OS in patients from Europe (HR = 1.48 [1.26, 1.74], P < 0.001) and worldwide multicenter studies (HR = 1.54 [1.24, 1.91], P < 0.001). The PPI use in patients with age less than or equal to 65, was found to be significantly associated to poor OS in the subgroup analysis related to age (HR = 1.56 [1.14, 2.15], P = 0.006). With regard to the subgroup of sample size, the usage of PPI was found to be significantly associated to poor OS in studies with sample sizes less than or equal to 300 (HR = 1.37 [1.02, 1.84], P = 0.04), and more than 300 (HR = 1.27 [1.04, 1.56], P = 0.02). In the analysis of the subgroup of immunotherapy drugs, the PPI use was found to be significantly related to poor OS in patients who had received PD-1 treatment (HR = 1.37 [1.04, 1.79], P = 0.03). With regard to the duration of PPI exposure subgroup, the result indicated that PPI use was significantly related to poor OS in patients who had received PPI treatment at 30 days before ICIs initiation (~30: HR = 1.89...
and 30 days before and after starting ICIs treatment (±30 days: HR = 1.44 [1.27, 1.64], \( P < 0.001 \)).

3.6. **Subgroup Analysis of PFS.** As in the subgroup analysis for OS, the PFS subgroup analyses were also performed with respect to region, age, sample size, immunotherapy drugs, and duration of PPI exposure, as shown in Table 4. In term of region subgroup, the use of PPI was significantly related to poor PFS in patients from Europe (HR = 1.36 [1.18, 1.57], \( P < 0.001 \)) and worldwide multi-center studies (HR = 1.34 [1.16, 1.55], \( P < 0.001 \)). The PPI usage indicated significant association with poor PFS in patients having age above 65 years (HR = 1.36 [1.18, 1.57], \( P < 0.001 \) in the age subgroup. In case of the sample size subgroup, the PPI use was found to be significantly related to poor PFS in studies with the sample size more than 300 (HR = 1.23 [1.04, 1.44], \( P = 0.01 \)). With regard to the subgroup analysis of immunotherapy drugs, PPI use was found to be significantly related to poor PFS in

| Author          | Year | Age | Region   | Cancer type | ICI treatment | PPI treatment                                      | No. of PPI | Patients | PPI exposure |
|-----------------|------|-----|----------|-------------|---------------|---------------------------------------------------|------------|----------|--------------|
| Chalabi et al.  | 2020 | NA  | Worldwide| NSCLC       | PD-L1         | Omeprazole, pantoprazole, lansoprazole, rabeprazole, esomeprazole, dexlansoprazole | 234        | 757      | Prior, within (30 days) |
| Hakoizaki et al.| 2019 | 67  | Asia     | NSCLC       | PD-1          | NA                                                | 47         | 90       | Prior (30 days) |
| Svaton et al.   | 2020 | 67  | Europe   | NSCLC       | PD-1          | Omeprazole, pantoprazole, lansoprazole            | 64         | 224      | Prior, within (30 days) |
| Zhao et al.     | 2019 | 62  | Asia     | NSCLC       | PD-1, other   | NA                                                | 40         | 109      | Prior, within (30 days) |
| Stokes et al.   | 2021 | 69  | America  | NSCLC       | PD-(L)1       | Omeprazole (majority)                             | 2159       | 3634     | Within (90 days) |
| Miura et al.    | 2021 | 65  | Asia     | NSCLC       | PD-1          | Lansoprazole, rabeprazole, Esomeprazole           | 163        | 300      | Within        |
| Cortellini et al.| 2021 | 70.1| Europe   | NSCLC       | PD-L1         | NA                                                | 474        | 950      | Prior, within (30 days) |
| Giordan et al.  | 2021 | 63.9| Worldwide| NSCLC       | PD-(L)1       | Pantoprazole, esomeprazole, lansoprazole, Rabeprazole, omeprazole | 47         | 212      | Prior (30 days) |
| Hopkins et al.  | 2022 | NA  | Oceania  | NSCLC       | PD-(L)1       | NA                                                | 441        | 1202     | Prior, within (30 days) |
| Hopkins et al.  | 2022 | NA  | Oceania  | NSCLC       | PD-L1         | Omeprazole, pantoprazole, esomeprazole, lansoprazole, rabeprazole, dexlansoprazole, vanoprazan | 1225       | 4458     | Within        |
| Husain et al.   | 2021 | NA  | America  | NSCLC       | PD-(L)1       | NA                                                | 149        | 415      | Within        |

NSCLC, non-small cell lung cancer; PPI, proton pump inhibitor; PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand 1; NA, not available; ICI, immune checkpoint inhibitor.

| Author          | Year | Method | Outcome | HR (95% CI) for OS | HR (95% CI) for PFS | Analysis | NOS score |
|-----------------|------|--------|---------|--------------------|---------------------|----------|-----------|
| Chalabi et al.  | 2020 | RE     | OS/PFS  | 1.45 (1.20–1.75)   | 1.30 (1.10–1.53)    | NA       | 8         |
| Hakoizaki et al.| 2019 | RE     | OS      | 1.90 (0.80–4.51)   | NA                  | M        | 6         |
| Svaton et al.   | 2020 | RE     | OS/PFS  | 1.22 (0.72–2.05)   | 1.36 (0.89–2.06)    | M        | 8         |
| Zhao et al.     | 2019 | RE     | OS/PFS  | 0.68 (0.33–1.43)   | 0.91 (0.54–1.54)    | U        | 8         |
| Stokes et al.   | 2021 | RE     | OS      | 0.96 (0.89–1.04)   | NA                  | M        | 7         |
| Miura et al.    | 2021 | RE     | OS      | 1.36 (0.96–1.91)   | NA                  | M        | 7         |
| Cortellini et al.| 2021 | RE    | OS/PFS  | 1.51 (1.28–1.80)   | 1.36 (1.17–1.59)    | U        | 8         |
| Giordan et al.  | 2021 | RE     | OS/PFS  | 1.89 (1.23–2.90)   | 1.51 (1.11–2.05)    | M        | 7         |
| Hopkins et al.  | 2022 | RE     | OS/PFS  | 1.53 (1.21–1.95)   | 1.34 (1.12–1.61)    | U        | 7         |
| Hopkins et al.  | 2022 | RE     | OS/PFS  | 1.00 (0.85–1.17)   | 0.93 (0.76–1.13)    | U        | 8         |
| Husain et al.   | 2021 | RE     | OS      | 1.43 (1.06–1.92)   | NA                  | U        | 6         |

OS, overall survival; PFS, progression-free survival; HR, hazard ratio; NA, not available; U, univariate; M, multivariate; NOS, Newcastle-Ottawa Scale; RE, retrospective.
| Study or Subgroup | log [Hazard Ratio] | SE  | Weight % | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|------------------|-------------------|-----|----------|--------------------------------|--------------------------------|
| Chalabi 2020     | 0.37156356        | 0.09624853  | 11.9     | 1.45 [1.20, 1.75]               |                               |
| Cortellini 2021  | 0.41210965        | 0.08697107  | 12.2     | 1.51 [1.27, 1.79]               |                               |
| Giorgdan 2021    | 0.63657683        | 0.21880015  | 7.4      | 1.89 [1.23, 2.90]               |                               |
| Hakozaki 2019    | 0.64185389        | 0.44118385  | 3.0      | 1.90 [0.80, 4.51]               |                               |
| Hopkins, AM 2022 | 0                 | 0.08151089  | 12.4     | 1.00 [0.85, 1.17]               |                               |
| Hopkins 2022     | 0.42526773        | 0.12173699  | 10.9     | 1.53 [1.21, 1.94]               |                               |
| Husain 2021      | 0.35767444        | 0.15154497  | 9.8      | 1.43 [1.06, 1.92]               |                               |
| Miura 2021       | 0.3074847         | 0.17549113  | 8.9      | 1.36 [0.96, 1.92]               |                               |
| Stokes 2021      | -0.04082199       | 0.0397333   | 13.5     | 0.96 [0.89, 1.04]               |                               |
| Svaton 2020      | 0.19885086        | 0.26692445  | 6.0      | 1.22 [0.72, 2.06]               |                               |
| Zhao 2019        | -0.38566248       | 0.37406558  | 3.9      | 0.68 [0.33, 1.42]               |                               |

Total (95% CI): 1.30 [1.10, 1.54]  
Heterogeneity: Tau² = 0.05; Chi² = 55.41, df = 10 (P < 0.00001); I² = 82%
Test for overall effect: Z = 3.01 (P = 0.003)

---

**Figure 2:** The forest plots of the hazard ratios (HRs) and 95% CIs for overall survival (a) and progression-free survival (b).

**Table 3:** The subgroup analysis of the correlation between the use of PPI and clinical efficacy of ICIs for overall survival.

| Subgroup          | No. of studies | OS hazard ratios (95% CI) | P-value | Heterogeneity I² (%) | P-value |
|-------------------|----------------|----------------------------|---------|----------------------|---------|
| **Region**        |                |                            |         |                      |         |
| Worldwide         | 2              | 1.54 [1.24, 1.91]          | <0.001  | 19.00                | 0.27    |
| Asia              | 3              | 1.21 [0.74, 1.98]          | 0.44    | 47.00                | 0.15    |
| Europe            | 2              | 1.48 [1.26, 1.74]          | <0.001  | 0                    | 0.45    |
| America           | 2              | 1.14 [0.77, 1.68]          | 0.51    | 85.00                | 0.01    |
| Oceania           | 2              | 1.23 [0.81, 1.86]          | 0.34    | 88.00                | 0.004   |
| **Age**           |                |                            |         |                      |         |
| ≤65               | 3              | 1.56 [1.14, 2.15]          | 0.006   | 27.00                | 0.24    |
| >65               | 4              | 1.26 [0.89, 1.79]          | 0.19    | 88.00                | <0.001  |
| **Sample size**   |                |                            |         |                      |         |
| ≤300              | 5              | 1.37 [1.02, 1.84]          | 0.04    | 37.00                | 0.17    |
| >300              | 6              | 1.27 [1.04, 1.56]          | 0.02    | 89.00                | <0.001  |
| **Immunotherapy drug** |            |                            |         |                      |         |
| PD-L1             | 3              | 1.30 [0.99, 1.69]          | 0.06    | 86.00                | <0.001  |
| PD-1              | 3              | 1.37 [1.04, 1.79]          | 0.03    | 0                    | 0.69    |
| PD-1, other       | 1              | 0.68 [0.33, 1.42]          | 0.3     | NA                   | NA      |
| PD-(L)1           | 4              | 1.37 [0.98, 1.92]          | 0.07    | 88.00                | <0.001  |
| **PPI exposure**  |                |                            |         |                      |         |
| −30               | 2              | 1.89 [1.29, 2.78]          | 0.001   | 0                    | 0.99    |
| +30               | 5              | 1.44 [1.27, 1.64]          | <0.001  | 19.00                | 0.3     |
| ∞                 | 4              | 1.10 [0.93, 1.30]          | 0.27    | 69.00                | 0.02    |

OS, overall survival; PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand 1; HR, hazard ratio; NA, not available; PPI, proton pump inhibitors.
patients having received PD-L1 treatment (HR = 1.33 [1.19, 1.49], P < 0.001). In case of subgroup regarding duration of PPI exposure, the result revealed that PPI use was significantly associated with poor PFS in patients treated with PPI at 30 days before starting the ICI treatments (−30: HR = 1.51 [1.11, 2.05], P = 0.008), and 30 days before and after starting the ICI treatments (±30: HR = 1.32 [1.20, 1.45], P < 0.001).

3.7. Publication Bias. The funnel plots assisted in assessing the publication bias, while the results revealed that there was no significant asymmetry about HR (OS or PFS), confirming that there was little possibility of publication bias (Figures 3(a) and 3(b)). In addition, Begg’s tests and Egger’s tests were also used to verify whether there is publication bias. As shown in Figures 3(c) and 3(d), there was no significant publication bias in the HR value of OS (Begg’s test, P = 0.640; Egger’s test, P = 0.059) and PFS (Begg’s test, P = 0.368; Egger’s test, P = 0.724).

3.8. Sensitivity Analysis. We performed sensitivity analysis on the included literature. It is obvious from the results that no single study had a great impact on the final combined HR value of OS and PFS. Therefore, we believe that the combined results of this study were reliable and robust (Figures 4(a) and 4(b)).

4. Discussion

The clinical efficacy or survival outcome of the use of PPI combined with IClIs in patients with NSCLC has not been known properly. Nevertheless, the following points deserve our attention. First, PPI has been proved to play a pivotal role in operating the immunologic defense to the treatment of tumors by regulating the activity or compositions of the gastrointestinal bacteria [18]. Second, for patients with gastric ulcers or gastrointestinal bleeding history, PPI could prophylactically be used to prevent the occurrence of stress ulcers [10]. Third, since PPI could greatly increase the sensitivity of cancer patients to chemotherapy, it was often used together with other types of anticancer drugs, such as ICIs, nonetheless, the clinical efficacy of the combination has remained unknown until today. Finally, whether the combination of PPI and ICIs would increase the adverse reactions related to the two drugs. For example, the long-term use of omeprazole would correspondingly increase the risk of liver failure and chronic kidney disease, thus affecting the efficacy of cancer treatment. A study revealed that the PPI use would significantly impact the composition of the gastrointestinal bacteria and greatly reduce the clinical efficacy of ICIs [19, 20]. In the study of Derosa et al. [21], it is shown that for advanced renal cell carcinoma and NSCLC patients, the use of antibiotics combined with ICIs would also lead to poor OS and PFS, which may be due to the fact that antibiotics greatly inhibit the diversity and abundance of intestinal flora, leading to the inability to fully mobilize the immune function. This may be similar to the reason why PPI combined with ICIs produced poor clinical efficacy. Other studies revealed that the PPI use would not have any influence on the clinical efficacy of ICIs [22]. Hence, to determine the correlation between the clinical efficacy of ICIs in NSCLC and the use of PPI, a meta-analysis was conducted.

On the one hand, compared with the study of Wei et al., Li et al., Qin et al., and Sophia et al. [10, 15, 23, 24], this study included more studies on NSCLC (n = 11 vs. n = 6 for Wei

| Subgroup | No. of studies | PFS hazard ratios (95% CI) | P value | Heterogeneity |
|----------|----------------|---------------------------|---------|--------------|
| Region   |                |                           |         |              |
| Worldwide| 2              | 1.34 [1.16, 1.55]         | <0.001  | 0            |
| Asia     | 1              | 0.91 [0.54, 1.54]         | 0.72    | NA           |
| Europe   | 2              | 1.36 [1.18, 1.57]         | <0.001  | 0            |
| Oceania  | 2              | 1.12 [0.78, 1.60]         | 0.54    | 86.00        |
| Age      |                |                           |         |              |
| ≤65      | 2              | 1.23 [0.75, 2.00]         | 0.41    | 63.00        |
| >65      | 2              | 1.36 [1.18, 1.57]         | <0.001  | 0            |
| Sample size |            |                           |         |              |
| ≤300     | 3              | 1.31 [1.00, 1.71]         | 0.05    | 25.00        |
| >300     | 4              | 1.23 [1.04, 1.44]         | 0.01    | 71.00        |
| Immunotherapy drug | |                   |         |              |
| PD-L1    | 2              | 1.33 [1.19, 1.49]         | <0.001  | 0            |
| PD-1     | 1              | 1.36 [0.89, 2.07]         | 0.15    | NA           |
| PD-1, other | 1            | 0.91 [0.54, 1.54]         | 0.72    | NA           |
| PD-(L)1  | 3              | 1.17 [0.73, 1.88]         | 0.52    | 85.00        |
| PPI exposure |          |                           |         |              |
| −30      | 1              | 1.51 [1.11, 2.05]         | 0.008   | NA           |
| ±30      | 5              | 1.32 [1.20, 1.45]         | <0.001  | 0            |
| ∞        | 1              | 0.93 [0.76, 1.13]         | 0.47    | NA           |

PFS, progression-free survival; PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand 1; HR, hazard ratio; NA, not available.
Figure 3: The Publication bias. (a) Funnel plot analysis of overall survival (OS). (b) Funnel plot analysis of progression-free survival (PFS). (c) Begg’s funnel plots for evaluating the publication bias of overall survival (OS). (d) Begg’s funnel plots for evaluating the publication bias of progression-free survival (PFS).

Figure 4: The sensitivity analysis. (a) Sensitivity analysis for hazard ratio (HR) of overall survival (OS). (b) Sensitivity analysis for hazard ratio (HR) of progression-free survival (PFS).
et al., n = 7 for Li et al., n = 7 for Qin et al., n = 4 for Sophia et al.) and more patients (n = 7,893 vs. n = 5,114 for Wei et al., n = 1,428 for Li et al., n = 3,647 for Qin et al., n = 2,940 for Sophia et al.), especially including two articles published in 2022. On the other hand, based on more factors, like the duration of exposure to PPI, the PPI treatment, type of ICI treatment, sample size, age, and region, the subgroup analysis was conducted. It would further help to understand the actual role of PPI in the combined use of ICIs drugs in cancer treatment. Hence, it is believed that our study has been very necessary and could provide certain basis for the rationale in the usage of PPI in clinical practices.

In patients treated with ICIs, the result indicated that PPI use was associated significantly to poor PFS (HR: 1.25 [1.09–1.42]) and poor OS (HR: 1.30 [1.10–1.54]). Nonetheless, in patients who had received ICIs treatment, the PPI use was not found to be associated with PFS and OS according to the study of Li et al. and Meng et al. [15, 25] in 2020. This could be due to the fact that the PPI use would lead to greater changes in the activity and composition of the gastrointestinal microbiota, which would be related to the tolerance of the T-cells. Simultaneously, the PPI use would not only affect the microbiota of gastrointestinal tract, but also would have a certain impact on the growth, metastasis, and progression of the tumor. In the study of De Milito et al. and Bellone et al. [26, 27], it was proposed that PPI could impact the tumor growth and metastasis by regulating the acidic microenvironment of the tissues around tumors. Meanwhile, the use of PPI severely inhibited the hydrogen ion ATPase pump, thus reversing the pH gradient of acidic microenvironment [27]. Besides, the use of PPI greatly promoted the generation of M2-subtype macrophages and pro-inflammatory cytokines (such as interleukin 7) [28]. All of these will reduce the immunosuppressive ability of tumor microenvironment and greatly inhibit the activity of ICIs [29]. Moreover, PPI would also increase the sensitivity of patients to chemotherapy and immunotherapy [9]. Hence, based on the PPI use, predicting the clinical efficacy of ICIs in NSCLC patients is highly difficult. Besides, further basic and relevant clinical studies would be required.

On factors like duration of PPI exposure, type of ICIs treatment, sample size, age, and region, a subgroup analysis was conducted to explore further the correlation between the clinical efficacy of ICIs and the use of PPI. PPI use was found to be significantly related to poor OS in case of the analysis on the region subgroup (Europe: HR = 1.48 [1.26, 1.74], Worldwide: HR = 1.54 [1.24, 1.91]) and poor PFS (Europe: HR = 1.36 [1.18, 1.57], Worldwide: HR = 1.34 [1.16, 1.55]) in patients from Europe and worldwide multi-center studies. It was suggested that the multi-center research projects need to be promoted between regions and countries. In term of sample size subgroup, PPI usage was found to be significantly related to poor OS in studies with the sample size less than or equal to 300 (HR = 1.37 [1.02, 1.84]), and more than 300 (HR = 1.27 [1.04, 1.56]), and poor PFS in studies with the sample size more than 300 (HR = 1.23 [1.04, 1.44]). In clarifying the correlation between clinical efficacy of ICIs and the PPI usage, the sample size played a crucial role, as confirmed from the results, and it has been recommended to include as many relevant samples as possible in clinical studies. For age subgroup, PPI use was significantly related to poor OS in patients with age less than or equal to 65 years (HR = 1.56 [1.14, 2.15]), and to poor PFS in patients with age more than 65 years (HR = 1.36 [1.18, 1.57]). People of different ages have different sensitivities to PPI. Hence, the clinical use of PPI needs to be cautious. With regard to the duration of PPI exposure subgroup, the PPI use was found to be significantly related to poor OS (–30: HR = 1.89 [1.29, 2.78], ±30: HR = 1.44 [1.27, 1.64]) and poor PFS (–30: HR = 1.51 [1.11, 2.05], ±30: HR = 1.32 [1.20, 1.45]) in patients treated with PPI drugs at 30 days before and/or after starting ICIs treatment. In the clinic, we need to stop the application of PPI immediately before and/or after starting the ICIs treatment, so as to provide the patients with good therapeutic effect. Finally, for type of ICIs treatment subgroup, PPI use displayed a poor prognosis for patients having received PD-L1 or PD-1 treatment, which possibly was related to the limited sample size included in this study. In addition, based on the above discussion, we suggest that when PPI is used in combination with ICIs in clinical practice, appropriate adjustment of the dysbiosis of organism and gastrointestinal bacterial colony disorder caused by the use of PPI may greatly improve the clinical efficacy and prognosis of relevant patients. Hence, to clarify the relationship between the clinical efficacy of ICIs in NSCLC and the PPI usage, more relevant research would be needed.

Our study had certain limitation. First, some PFS data were missing in the included studies, and this study only extracted the HR value and 95% CI value of the included study rather than the initial data of the study, which could have a greater impact on our results. Second, the studies included were retrospective studies. In the process of extracting data, such as sample size, type of ICIs treatment, and duration of PPI exposure, region, and age, the detailed information of relevant data could not be known, which could lead to certain limitations in the overall and subgroup analysis of this study. Third, this study only included studies published in English, while those published in other languages, for instance, Chinese, were not included, which could indirectly lead to increased heterogeneity of this study. Finally, it was found that there was no direct study proving the association between the PPI use and the clinical efficacy of ICIs in NSCLC. Hence, more research related to this becomes imperative.

5. Conclusion

In conclusion, our meta-analysis found that PPI combined with ICIs in the treatment of NSCLC patients possibly resulted in poor OS and PFS. In term of subgroup analysis, PPI use had a poor prognosis for patients having received PD-L1 or PD-1 treatment, or those who received PPI drugs at 30 days before and/or after ICIs initiation. Simultaneously, the effect of PPI on patients of different age groups was also different. Hence, in clinical practice, we need to be extremely cautious in the PPI use to avoid the influence in the efficacy of ICIs. Nevertheless, the concrete mechanism between the use of PPI and the efficacy of ICIs needs to be
further studied, so as to further improve the clinical treatment level of the related tumors.

Data Availability

All data generated or analyzed in order to support the findings of this study are included within the article.

Conflicts of Interest

The authors state that the study was conducted without any business or financial relationships that could be interpreted as potential conflicts of interest.

Authors’ Contributions

Da-Hai Hu, Wan-Ching Wong, and Jia-xin Zhou contributed equally to this work. D. H. and W. W. designed the research. D. H. and J. Z. collected and analyzed the data. D. H. and W. W. wrote the original draft. H. T., S. C., and H. Z. revised the first draft.

Acknowledgments

This project was supported by Guangdong Province Medical Science and Technology Research Fund Project (A2021056).

References

[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
[2] F. Nasim, B. F. Sabath, and G. A. Eapen, "Lung cancer," Medical Clinics of North America, vol. 103, no. 3, pp. 463–473, 2019.
[3] R. S. Herbst, D. Morgensztern, and C. Boshoff, "The biology and management of non-small cell lung cancer," Nature, vol. 553, no. 7689, pp. 446–454, 2018.
[4] G. H. Kim, "Proton pump inhibitor-related gastric mucosal changes," Gut and liver, vol. 15, no. 5, pp. 646–652, 2021.
[5] F. Imhann, M. J. Bonder, A. Vich Vila et al., "Proton pump inhibitors affect the gut microbiome," Gut, vol. 65, no. 5, pp. 740–748, 2016.
[6] D. Y. Graham and R. M. Genta, "Long-term proton pump inhibitor use and gastrointestinal cancer," Current Gastroenterology Reports, vol. 10, no. 6, pp. 543–547, 2008.
[7] P. Declinch, L. Ambrosiani, S. Bellone et al., "Parietal cell hyperplasia with deep cystic dilations: a lesion closely mimicking fundic gland polyps," American Journal of Gastroenterology, vol. 95, no. 2, pp. 566–568, 2000.
[8] S. Ferrari, F. Perut, F. Fagioli et al., "Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed," Journal of Translational Medicine, vol. 11, no. 1, p. 268, 2013.
[9] B. Y. Wang, J. Zhang, J. L. Wang, Z. Shao, S. Fais, and X. Hu, "P175 Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in MBC," The Breast, vol. 24, no. 1, p. 85, 2015.
[10] N. Wei, B. Zheng, W. Que, J. Zhang, and M. Liu, "The association between proton pump inhibitor use and systemic anti-tumour therapy on survival outcomes in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis," British Journal of Clinical Pharmacology, vol. 88, 2022.
[11] L. B. Kennedy and A. K. S. Salama, "A review of cancer immunotherapy toxicity," CA: A Cancer Journal for Clinicians, vol. 70, no. 2, pp. 86–104, 2020.
[12] B. Olson, Y. Li, Y. Lin, E. T. Liu, and A. Patnaik, "Mouse models for cancer immunotherapy research," Cancer Discovery, vol. 8, no. 11, pp. 1358–1365, 2018.
[13] C. Liu, H. Guo, H. Mao, J. Tong, M. Yang, and X. Yan, "An up-to-date investigation into the correlation between proton pump inhibitor use and the clinical efficacy of immune checkpoint inhibitors in advanced solid cancers: a systematic review and meta-analysis," Frontiers in Oncology, vol. 12, 2022.
[14] S. Tan, D. Li, and X. Zhu, "Cancer immunotherapy: pros, cons and beyond," Biomedicine & Pharmacotherapy, vol. 124, Article ID 109821, 2020.
[15] M. Li, C. Zeng, J. Yao, G. Yang, and G. An, "The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy," International Immunopharmacology, vol. 88, Article ID 106972, 2020.
[16] Y. Miu, L. Zhao, H. He, H. Zhao, and J. Li, "The efficacy of ileostomy after laparoscopic rectal cancer surgery: a meta-analysis," World Journal of Surgical Oncology, vol. 19, no. 1, p. 318, 2021.
[17] A. Stang, "Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses," European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010.
[18] X. Diao, "Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer," Thoracic Cancer, vol. 11, no. 7, pp. 1763–1764, 2020.
[19] A. M. Hopkins, G. Kichenadasse, C. S. Karapetis, A. Rowland, and M. J. Sorich, "Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab," Clinical Cancer Research, vol. 26, no. 20, pp. 5487–5493, 2020.
[20] Q. Le Bastard, L. Berthelot, J. P. Soulillou, and E. Montassier, "Impact of non-antibiotic drugs on the human intestinal microbiome," Expert Review of Molecular Diagnostics, vol. 21, no. 9, pp. 911–924, 2021.
[21] L. Derosa, M. D. Hellmann, M. Spaziano et al., "Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer," Annals of Oncology, vol. 29, no. 6, pp. 1437–1444, 2018.
[22] K. Peng, K. Chen, B. A. Teply, G. C. Yee, P. A. Farazi, and E. R. Lyden, "Impact of proton pump inhibitor use on the effectiveness of immune checkpoint inhibitors in advanced cancer patients," The Annals of Pharmacotherapy, vol. 56, no. 4, pp. 377–386, 2022.
[23] S. Dar, N. Merza, A. Qatanii et al., "Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis," Annals of Medicine and Surgery (2012), vol. 78, Article ID 103752, 2022.
[24] X.-D. J. Bao-Dong Qin, X.-C. Zhou, B. Shi et al., "Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer," OncolImmunology, vol. 11, Article ID e1929727, 2021.
[25] C. Li, Z. Xia, A. Li, and J. Meng, "The effect of proton pump inhibitor uses on outcomes for cancer patients treated with..."
immune checkpoint inhibitors: a meta-analysis,” *Annals of Translational Medicine*, vol. 8, no. 24, p. 1655, 2020.

[26] A. De Milito, R. Canese, M. L. Marino et al., “pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity,” *International Journal of Cancer*, vol. 127, no. 1, pp. 207–219, 2010.

[27] M. Bellone, A. Calcinotto, P. Filipazzi, A. De Milito, S. Fais, and L. Rivoltini, “The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors,” *OncoImmunology*, vol. 2, no. 1, Article ID e22058, 2013.

[28] N. K. Vishvakarma and S. M. Singh, “Immunopotentiating effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host: implication in antitumor activation of tumor-associated macrophages,” *Immunology Letters*, vol. 134, no. 1, pp. 83–92, 2010.

[29] Q. Giordan, J. Salleron, C. Vallance, C. Moriana, and C. Clement-Duchene, “Impact of antibiotics and proton pump inhibitors on efficacy and tolerance of anti-PD-1 immune checkpoint inhibitors,” *Frontiers in Immunology*, vol. 12, Article ID 716317, 2021.

[30] M. Chalabi, A. Cardona, D. R. Nagarkar et al., “Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials,” *Annals of Oncology*, vol. 31, no. 4, pp. 525–531, 2020.

[31] T. Hakozaki, Y. Okuma, M. Omori, and Y. Hosomi, “Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer,” *Oncology Letters*, vol. 17, no. 3, pp. 2946–2952, 2019.

[32] M. Svaton, M. Zemanova, P. Zemanova et al., "Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer," *Anticancer Research*, vol. 40, no. 4, pp. 2209–2217, 2020.

[33] S. Zhao, G. Gao, W. Li et al., "Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer," *Lung Cancer*, vol. 130, pp. 10–17, 2019.

[34] W. A. B. M. Stokes, M. Behera, R. Jiang et al., "Association of proton pump inhibitors with survival in veterans with non-small cell lung cancer receiving immunotherapy," *Journal of Clinical Oncology*, vol. 39, Article ID e18729, 2021.

[35] K. Miura, Y. Sano, S. Niho et al., "Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study," *Thoracic Cancer*, vol. 12, no. 13, pp. 1983–1994, 2021.

[36] A. Cortellini, M. Di Maio, O. Nigro et al., "Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy," *Journal for ImmunoTherapy of Cancer*, vol. 9, no. 4, Article ID e002421, 2021.

[37] A. M. Hopkins, G. Kichenadasse, R. A. McKinnon et al., "Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMPower150," *British Journal of Cancer*, vol. 126, no. 1, pp. 42–47, 2022.

[38] A. M. Hopkins, S. Badaoui, G. Kichenadasse et al., "Efficacy of atezolizumab in patients with advanced NSCLC receiving concomitant antibiotic or proton pump inhibitor treatment:

pooled analysis of five randomized control trials," *Journal of Thoracic Oncology*, vol. 17, 2022.

[39] M. X. M. Husain, S. Patel, A. Johns, M. Grogan, and M. Li, "P40.15 proton pump inhibitors, prior therapy and survival in patients treated with immune checkpoint inhibitors for advanced NSCLC," *Journal of Thoracic Oncology*, vol. 16, 2021.